product summary
company name :
Ventana
product type :
antibody
product name :
Progesterone Receptor
catalog :
790-2223
clonality :
monoclonal
host :
rabbit
conjugate :
nonconjugated
clone name :
1E2
reactivity :
human, cat
application :
immunohistochemistry, immunohistochemistry - paraffin section
more info or order :
citations: 6
Published Application/Species/Sample/DilutionReference
  • immunohistochemistry; human; 1:50; loading ...; fig 3b
Browne A, Charmsaz S, Varešlija D, Fagan A, Cosgrove N, Cocchiglia S, et al. Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer. Oncogene. 2018;37:2008-2021 pubmed publisher
  • immunohistochemistry - paraffin section; human; loading ...; fig 2b
Nielsen T, Jensen M, Burugu S, Gao D, Jørgensen C, Balslev E, et al. High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial. Clin Cancer Res. 2017;23:946-953 pubmed publisher
  • immunohistochemistry; human; fig 1a
Ladd B, Mazzola A, Bihani T, Lai Z, BRADFORD J, Collins M, et al. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations. Oncotarget. 2016;7:54120-54136 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:1; tbl 3
Leo F, Bartels S, Mägel L, Framke T, Büsche G, Jonigk D, et al. Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer. Virchows Arch. 2016;469:191-201 pubmed publisher
  • immunohistochemistry - paraffin section; cat; loading ...; tbl 4
Soares M, Ribeiro R, Najmudin S, Gameiro A, Rodrigues R, Cardoso F, et al. Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status. Oncotarget. 2016;7:17314-26 pubmed publisher
  • immunohistochemistry; cat; loading ...; fig 1b
Soares M, Correia J, Peleteiro M, Ferreira F. St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study. Tumour Biol. 2016;37:4053-64 pubmed publisher
company information